HK1055260A1 - Stabilization of solid thyroid drug formulations - Google Patents

Stabilization of solid thyroid drug formulations

Info

Publication number
HK1055260A1
HK1055260A1 HK03107626A HK03107626A HK1055260A1 HK 1055260 A1 HK1055260 A1 HK 1055260A1 HK 03107626 A HK03107626 A HK 03107626A HK 03107626 A HK03107626 A HK 03107626A HK 1055260 A1 HK1055260 A1 HK 1055260A1
Authority
HK
Hong Kong
Prior art keywords
stabilization
drug formulations
forms
excipients
thyroid drug
Prior art date
Application number
HK03107626A
Other languages
English (en)
Inventor
Spiridon Spireas
Original Assignee
Sigmapharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigmapharm Inc filed Critical Sigmapharm Inc
Publication of HK1055260A1 publication Critical patent/HK1055260A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
HK03107626A 2000-10-03 2003-10-22 Stabilization of solid thyroid drug formulations HK1055260A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23744200P 2000-10-03 2000-10-03
US09/690,973 US6855333B1 (en) 2000-10-03 2000-10-18 Stabilization of solid thyroid drug formulations
PCT/US2001/029986 WO2002028364A2 (en) 2000-10-03 2001-09-26 Stabilization of solid thyroid drug formulations

Publications (1)

Publication Number Publication Date
HK1055260A1 true HK1055260A1 (en) 2004-01-02

Family

ID=26930677

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03107626A HK1055260A1 (en) 2000-10-03 2003-10-22 Stabilization of solid thyroid drug formulations

Country Status (14)

Country Link
US (1) US6855333B1 (xx)
EP (1) EP1322294B1 (xx)
CN (1) CN1543341A (xx)
AT (1) ATE380543T1 (xx)
AU (2) AU2001291244B2 (xx)
CA (4) CA2641570C (xx)
CY (1) CY1107295T1 (xx)
DE (1) DE60131863T2 (xx)
ES (1) ES2298262T3 (xx)
HK (1) HK1055260A1 (xx)
MX (1) MXPA03002809A (xx)
NZ (1) NZ524567A (xx)
PT (1) PT1322294E (xx)
WO (1) WO2002028364A2 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
WO2002072069A1 (en) * 2001-03-12 2002-09-19 Novo Nordisk A/S Novel tablets and capsules and a process for its preparation
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
US10231931B1 (en) 2018-03-23 2019-03-19 Genus Lifesciences Inc. Thyroid hormone oral dosage forms and methods of using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001211A (en) * 1974-12-02 1977-01-04 The Dow Chemical Company Pharmaceutical capsules from improved thermogelling methyl cellulose ethers
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5051406A (en) 1987-03-04 1991-09-24 Nippon Hypox Laboratories Incorporated Pharmaceutical composition using albumin as a carrier and process for producing the same
US4983399A (en) * 1989-10-18 1991-01-08 Eastman Kodak Company Direct compression carrier composition
US5225204A (en) * 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
DE4318577A1 (de) 1993-06-04 1994-12-08 Merck Patent Gmbh Schmiermittelfreie, arzneimittelhaltige Tabletten
EP0729748B1 (en) 1993-11-18 2003-02-26 Nippon Shinyaku Company, Limited Process for producing stable medicinal composition
GB9401892D0 (en) 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
CA2159419C (en) 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water
US5756123A (en) * 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
DE19541128C2 (de) 1995-10-27 1997-11-27 Henning Berlin Gmbh & Co Stabilisierte schilddrüsenhormonhaltige Arzneimittel
US5635209A (en) 1995-10-31 1997-06-03 Vintage Pharmaceuticals, Inc. Stabilized composition of levothyroxine sodium medication and method for its production
EP0861073B1 (en) * 1995-11-14 2004-07-28 Abbott GmbH & Co. KG Stabilized thyroid hormone preparations and methods of making same
CZ333698A3 (cs) 1996-04-16 1999-01-13 Bayer Ag D-mannitol a způsob jeho přípravy
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same

Also Published As

Publication number Publication date
CA2641575C (en) 2014-04-08
CA2423572A1 (en) 2002-04-11
DE60131863D1 (de) 2008-01-24
ES2298262T3 (es) 2008-05-16
DE60131863T2 (de) 2008-12-11
PT1322294E (pt) 2008-02-28
AU9124401A (en) 2002-04-15
WO2002028364A3 (en) 2002-06-06
CN1543341A (zh) 2004-11-03
CA2641581C (en) 2011-11-29
CA2641575A1 (en) 2002-04-11
EP1322294A2 (en) 2003-07-02
EP1322294B1 (en) 2007-12-12
NZ524567A (en) 2004-12-24
MXPA03002809A (es) 2004-09-10
CA2641581A1 (en) 2002-04-11
CA2641570A1 (en) 2002-04-11
AU2001291244B2 (en) 2006-09-21
CA2423572C (en) 2009-01-06
CY1107295T1 (el) 2012-11-21
CA2641570C (en) 2014-04-22
WO2002028364A2 (en) 2002-04-11
US6855333B1 (en) 2005-02-15
ATE380543T1 (de) 2007-12-15

Similar Documents

Publication Publication Date Title
MXPA03002807A (es) Estabilizacion de formulaciones solidas de farmacos.
HK1096034A1 (en) A solid dosage form comprising a fibrate
CY1107295T1 (el) Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους
DE60231298D1 (de) Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
IL138767A0 (en) Anticancer compositions
EA200301275A1 (ru) Капсулы для ингаляции
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
GEP20053473B (en) High Potency Dihydroergotamine Compositions
EP1391200A4 (en) DRUG
HK1029060A1 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
WO2002015959A3 (en) Compounds and compositions for delivering active agents
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
MY131488A (en) Low dose liquid entecavir formulations and use
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
WO2003013441A3 (en) Levothyroxine compositions and methods
WO2004014318A3 (en) Levothyroxine compositions and methods
SE0203817D0 (sv) New composition
BG106368A (en) Pharmaceutical composition and its preparation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200926